179 related articles for article (PubMed ID: 14966683)
41. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
[TBL] [Abstract][Full Text] [Related]
42. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
[TBL] [Abstract][Full Text] [Related]
43. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
44. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
45. Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas.
Mueller W; Lass U; Wellmann S; Kunitz F; von Deimling A
Acta Neuropathol; 2005 Mar; 109(3):314-20. PubMed ID: 15668788
[TBL] [Abstract][Full Text] [Related]
46. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas.
Parhar P; Ezer R; Shao Y; Allen JC; Miller DC; Newcomb EW
Brain Res Mol Brain Res; 2005 Jun; 137(1-2):98-103. PubMed ID: 15950766
[TBL] [Abstract][Full Text] [Related]
47. Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia.
Preudhomme C; Lubin R; Lepelley P; Vanrumbeke M; Fenaux P
Leukemia; 1994 Sep; 8(9):1589-91. PubMed ID: 8090036
[TBL] [Abstract][Full Text] [Related]
48. Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors.
Söling A; Plugge EM; Schmitz M; Weigle B; Jacob R; Illert J; Holzhausen HJ; Rainov NG
Int J Oncol; 2007 Jan; 30(1):123-8. PubMed ID: 17143520
[TBL] [Abstract][Full Text] [Related]
49. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas.
Wakabayashi T; Natsume A; Hatano H; Fujii M; Shimato S; Ito M; Ohno M; Ito S; Ogura M; Yoshida J
Neurosurgery; 2009 Mar; 64(3):455-61; discussion 461-2. PubMed ID: 19240607
[TBL] [Abstract][Full Text] [Related]
50. [The relationship between serum anti-p53 antibodies and the expression of p53 gene with the differentiation of primary hepatic carcinoma].
Guan YS; La Z; He Q; Hu Y; Liu Y
Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):467-8. PubMed ID: 18579003
[No Abstract] [Full Text] [Related]
51. Brainstem gliomas--a clinicopathological study of 45 cases with p53 immunohistochemistry.
Badhe PB; Chauhan PP; Mehta NK
Indian J Cancer; 2004; 41(4):170-4. PubMed ID: 15659871
[TBL] [Abstract][Full Text] [Related]
52. Prognostic implications of circulating anti-p53 antibodies in lung cancer--a review.
Kumar S; Mohan A; Guleria R
Eur J Cancer Care (Engl); 2009 May; 18(3):248-54. PubMed ID: 19432918
[TBL] [Abstract][Full Text] [Related]
53. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway.
Newton HB
Expert Rev Anticancer Ther; 2005 Feb; 5(1):177-91. PubMed ID: 15757449
[TBL] [Abstract][Full Text] [Related]
54. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
55. A high degree of aneuploidy, loss of p53 gene, and low soluble p53 protein serum levels are detected in ulcerative colitis patients.
Rosman-Urbach M; Niv Y; Birk Y; Smirnoff P; Zusman I; Morgenstern S; Schwartz B
Dis Colon Rectum; 2004 Mar; 47(3):304-13. PubMed ID: 14991492
[TBL] [Abstract][Full Text] [Related]
56. Inheritance of R337H p53 gene mutation in children with sporadic adrenocortical tumor.
Sandrini F; Villani DP; Tucci S; Moreira AC; de Castro M; Elias LL
Horm Metab Res; 2005 Apr; 37(4):231-5. PubMed ID: 15952083
[TBL] [Abstract][Full Text] [Related]
57. p53 protein expression does not correlate with EBV status in childhood B non-Hodgkin lymphomas.
Klumb CE; Hassan R; Zalcberg IR; Resende LM; Carriço MK; Maia RC
Pediatr Blood Cancer; 2004 Aug; 43(2):115-9. PubMed ID: 15236276
[TBL] [Abstract][Full Text] [Related]
58. Genetic alterations in brain tumors following 1,3-butadiene exposure in B6C3F1 mice.
Kim Y; Hong HH; Lachat Y; Clayton NP; Devereux TR; Melnick RL; Hegi ME; Sills RC
Toxicol Pathol; 2005; 33(3):307-12. PubMed ID: 15814359
[TBL] [Abstract][Full Text] [Related]
59. Distribution of p53 alterations in a case of gliomatosis cerebri.
Mawrin C; Lins H; Kirches E; Schildhaus HU; Scherlach C; Kanakis D; Dietzmann K
Hum Pathol; 2003 Jan; 34(1):102-6. PubMed ID: 12605375
[TBL] [Abstract][Full Text] [Related]
60. Expression of the p53 family in lung cancer.
Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Nozoe T; Yasumoto K
Anticancer Res; 2006; 26(3A):1785-90. PubMed ID: 16827107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
